[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332235-105":59,"doc-detail-332235-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gene-expression-assays-to-tailor-adjuvant-endocrine-therapy-for-hrher2-breast-cancer","Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer","","Adjuvant endocrine therapy (ET) is standard for most HR+/HER2- breast cancers, yet choosing the right agent and duration remains uncertain because overtreatment can cause unnecessary toxicity. Biological biomarkers could complement clinicopathological factors to optimize decisions. Multiple gene expression assays help identify patients who do not benefit from adjuvant chemotherapy, improve risk stratification, and predict endocrine response. Evidence also supports genomic testing for extended ET and preliminary de-escalation strategies for low-risk patients, enabling more personalized care.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gene-expression-assays-to-tailor-adjuvant-endocrine-therapy-for-hrher2-breast-cancer/332235/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gene-expression-assays-to-tailor-adjuvant-endocrine-therapy-for-hrher2-breast-cancer/332235.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are gene expression assays important for HR+/HER2- breast cancer ET decisions?","Question",{"text":112,"@type":113},"They integrate biological information beyond clinicopathological features to optimize endocrine treatment, reducing unnecessary toxicity and improving risk stratification and response prediction.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence is reviewed for tailoring adjuvant endocrine therapy?",{"text":117,"@type":113},"Evidence supporting common commercially available gene expression assays (Oncotype DX, MammaPrint, BCI, Prosigna, EndoPredict) is discussed, including their role in extended treatment choice and de-escalation for low-risk patients.",{"name":119,"@type":110,"acceptedAnswer":120},"How do genomic assays contribute to decisions about extended versus de-escalated ET?",{"text":121,"@type":113},"Genomic tests help estimate benefit from prolonged ET based on late relapse risk, while preliminary evidence supports using genomic assays to identify low-risk patients who may be suitable for shorter duration or omission.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332235,1790691792,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2 − Breast Cancer  \nMichele Bottosso1,2, Federica Miglietta1,2, Grazia Maria Vernaci2, Tommaso Giarratano2, Maria Vittoria Dieci1,2, Valentina Guarneri1,2, and Gaia Griguolo1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Adjuvant endocrine therapy (ET) represents the standard of care for almost all hormone receptor (HR)+/HER2 􀀁 breast cancers, and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/ HER2 􀀁 breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant ET beyond currently used clinicopathological characteristics. Several gene expression assays have been developed to identify patients with HR+/HER2 􀀁 breast cancer who will not derive benefit from the addition of adjuvant chemotherapy. By enhancing risk stratification and predicting therapeutic response, genomic assays have also shown\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | to be a promising tool for optimizing endocrine treatment decisions. In this study, we review evidence supporting the use of most common commercially available gene expression assays [Oncotype DX, MammaPrint, Breast Cancer Index (BCI), Prosigna, and EndoPredict] in tailoring adjuvant ET. Available data on the use of genomic tests to inform extended adjuvant treatment choice based on the risk of late relapse and on the estimated benefit of a prolonged ET are discussed. Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low-risk patients is reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2 􀀁 breast cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nHormone receptor (HR)+/HER2 􀀁 breast cancer represents the most frequent breast cancer subtype, accounting for more than two thirds of new breast cancer diagnoses (1) . Adjuvant endocrine therapy (ET) has been widely recognized as a cornerstone in the clinical management of early-stage HR+/HER2 􀀁 breast cancers, providing a reduction of almost 40% in the risk of recurrence as well as a long-term reduction in breast cancer–related mortality (2) . Indeed, randomized trials have established different ET options with tamoxifen, aromatase inhibitors (AI), and, for high-risk premenopausal patients, ovarian function suppression (OFS), for at least 5 years as standard adjuvant therapy, which is routinely prescribed in almost all newly diagnosed HR+/HER2 􀀁 breast cancers (3, 4) . However, the optimal regimen and duration of ET for a s","cbCaiafMoyTAehSg","https://ap.wps.com/l/cbCaiafMoyTAehSg","pdf",1954251,11,"English","# Introduction\n## Clinical need for biomarkers in adjuvant endocrine therapy\n## Risk of late relapse and benefit of extended ET\n## Rationale for de-escalation in low-risk patients","[{\"question\":\"Why are gene expression assays important for HR+/HER2- breast cancer ET decisions?\",\"answer\":\"They integrate biological information beyond clinicopathological features to optimize endocrine treatment, reducing unnecessary toxicity and improving risk stratification and response prediction.\"},{\"question\":\"What evidence is reviewed for tailoring adjuvant endocrine therapy?\",\"answer\":\"Evidence supporting common commercially available gene expression assays (Oncotype DX, MammaPrint, BCI, Prosigna, EndoPredict) is discussed, including their role in extended treatment choice and de-escalation for low-risk patients.\"},{\"question\":\"How do genomic assays contribute to decisions about extended versus de-escalated ET?\",\"answer\":\"Genomic tests help estimate benefit from prolonged ET based on late relapse risk, while preliminary evidence supports using genomic assays to identify low-risk patients who may be suitable for shorter duration or omission.\"}]","Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer | PDF",1789997468,28]